What is Aquestive Therapeutics, Inc.'s 2030 and thereafter?

Aquestive Therapeutics, Inc. (AQST) reported 2030 and thereafter of $2.92M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s 2030 and thereafter changed year-over-year?

Aquestive Therapeutics, Inc.'s 2030 and thereafter decreased by 25.5% year-over-year, from $3.92M to $2.92M.

Aquestive Therapeutics, Inc. AQST 2030 and thereafter

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept aqst:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s 2030 and thereafter.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s 2030 and thereafter?: Aquestive Therapeutics, Inc. (AQST) reported 2030 and thereafter of $2.92M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s 2030 and thereafter changed year-over-year?: Aquestive Therapeutics, Inc.'s 2030 and thereafter decreased by 25.5% year-over-year, from $3.92M to $2.92M.